Combination of TG-1101, the Company's Novel Glycoenginereed Anti-CD20 Monoclonal Antibody and TGR-1202, the Company's Once Daily PI3K Delta Inhibitor to be Highlighted in Oral Presentation
Updates on the Combination of TG-1101 Plus Ibrutinib, and Single-Agent TGR-1202 to be Featured in Poster Presentations TG Therapeutics to Host a Reception on Monday December 8 th from 7:45 pm – 9:00 pm with Presentations by Leading Clinical Investigators
NEW YORK, Nov.
for TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting investment picks